Clinical trials: Autosomal Dominant Polycystic Kidney
Chronic Kidney Disease, Polycystic Kidney, Autosomal Dominant
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
The aim of this pilot project is to assess the potential of urine micro-RNAs (miRNA) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD) compared with patients with other causes of…
- Trial name
- NCT01114594
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The Rogosin Institute
Adult Polycystic Kidney Disease
Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease
In patients with polycystic kidney disease, pain may be resistant to drug therapy and may reduce quality of life. This study investigate the effect of renal denervation on this pain.
- Trial name
- NCT02062671
- Testing
- renal denervation
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Odense University Hospital
Polycystic Kidney, Autosomal Dominant
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
The aim of the study is to test the following hypotheses: 1. that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease. 2.
- Trial name
- NCT00410007
- Testing
- High Sodium Diet, Low Sodium Diet, Hypertonic saline infusion
- Where
- Denmark
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Carolina Cannillo
Autosomal Dominant Polycystic Kidney, Obesity
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can…
- Trial name
- NCT06582875
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Colorado, Denver
Kidney Disease
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given.
- Trial name
- NCT06734234
- Testing
- GSK4771261
- Where
- 23 sites in United States, Belgium and 6 more
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Autosomal Dominant Polycystic Kidney Disease
Effects of Somatostatin on Liver in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a variety of extrarenal manifestations of which polycystic liver disease is most common.
- Trial name
- NCT02119052
- Testing
- octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited cystic disorder characterised by the progressive degeneration of the renal parenchyma into cystic formations, with involvement of other organs to varying…
- Trial name
- NCT07535385
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Polycystic Kidney
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
Autosomal-Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, characterized by the progressive development of fluid-filled cysts in the kidney leading to progressive loss of renal function and…
- Trial name
- SIRENA (NCT00491517)
- Testing
- Sirolimus, conventional therapy
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD…
- Trial name
- ESSENTIAL (NCT03949894)
- Testing
- Tolvaptan
- Where
- 18 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Polycystic Kidney Disease
Polycystic Kidney Disease Data Repository
Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide.
- Trial name
- NCT00792155
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- The Rogosin Institute
Chronic Kidney Diseases, Alport Syndrome
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with…
- Conditions
- Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
- Trial name
- EAGLE (NCT03749447)
- Testing
- Bardoxolone methyl
- Where
- 87 sites in United States, Australia and 4 more
- Volunteers
- 270 people
- Sponsor
- Biogen
Autosomal Dominant Polycystic Kidney Disease
Intrarenal Microvasculature in ADPKD
The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and healthy…
- Trial name
- NCT05288998
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Lanreotide In Polycystic Kidney Disease Study
LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular…
- Trial name
- LIPS (NCT02127437)
- Testing
- Lanreotide, saline
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autosomal Dominant Polycystic Kidney
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
Investigator initiated controlled multi-centre trial in a Prospective, Randomised, Open, Blinded Endpoint (PROBE) design. Patients will be randomised in a 1:1 ratio either to treatment with tolvaptan for six weeks followed by six…
- Trial name
- PoCKET (NCT03596957)
- Testing
- Tolvaptan
- Where
- 6 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- Lisbet Brandi
ADPKD
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Individuals with a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) often have a family history of the condition although up to 10-15% of cases are sporadic mutations.
- Trial name
- NCT06085807
- Testing
- Survey
- Where
- United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Autosomal Dominant Polycystic Kidney Disease, Disease Progression
Efficacy Study of Water Drinking on PKD Progression.
This is a prospective 5-year study to compare the change in total kidney volume (TKV) before and after tolvaptan therapy, as the primary endpoint, in patients with ADPKD.
- Trial name
- ESWP (NCT01348035)
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kyorin University
Polycystic Kidney Disease
Early PKD Observational Cohort Study
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also…
- Trial name
- EPOC (NCT02936791)
- Where
- 3 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
ADPKD
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
The objective of this study is to measure the influence of both short term water restriction and high water intake on total kidney volume, measured by Magnetic Resonance Imaging (MRI) scan in Autosomal Dominant Polycystic Kidney…
- Trial name
- NCT02776241
- Testing
- water
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease (PKD) is the most common genetic disease leading to End Stage Kidney Disease (ESKD), affecting between 1 in 500-1000 individuals from every ethnic group.
- Trial name
- NCT05870007
- Testing
- Atorvastatin 20 Mg Oral Tablet, Sodium Bicarbonate 600 Mg Oral Tablet
- Where
- 3 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Autosomal Dominant Polycystic Kidney Disease
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
EuroCYST initiative aims to build a large, well-characterized cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) subjects who are followed in a longitudinal observational cohort study has the potential to identify…
- Trial name
- NCT02187432
- Where
- 14 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,100 people
- Sponsor
- Andreas L. Serra